Lakea

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lakea

Understanding Lakea

Lakea is a therapeutic agent designed to interact with specific biological pathways to manage particular health conditions. It belongs to a class of medications that target cellular mechanisms to influence the progression or symptoms of a disease state.

Mechanism of Action

The primary function of Lakea involves modulating specific receptors or enzymes within the body. By binding to these targets, the medication helps to regulate physiological processes that have become imbalanced. This targeted approach aims to stabilize the underlying biological environment associated with the condition it is intended to treat.

Clinical Applications

Lakea is utilized in clinical settings where specific intervention is required to address chronic or acute symptoms. Its application is based on the pharmacological profile of the active ingredients, which have been studied for their role in systemic or localized therapeutic effects. The objective of using Lakea is to support the body's functional equilibrium and provide a consistent response to the identified health concern.

Considerations for Use

When considering Lakea as part of a management plan, the focus is placed on the individual's overall health profile and the specific characteristics of their condition. As with many therapeutic interventions, the effectiveness of Lakea can vary based on biological factors and the presence of other physiological variables. It is intended to be used as a component of a comprehensive approach to health management.

Regulatory References

  1. Losartan: MedlinePlus Drug Information

What side effects are possible with Lakea?

Possible Side Effects and Safety Information

The safety profile of Lakea is structured around common central nervous system effects, gastrointestinal disturbances, and specific serious warnings documented in regulatory texts. Adverse reactions are classified by frequency based on the ICH/CIOMS framework (e.g., Very Common, Common, Uncommon, Rare).


Frequency Classification Key Adverse Reactions (System-Organ Class)
Very Common (≥1/10) Somnolence (Nervous System), Dry Mouth (Gastrointestinal), Headache (Nervous System)
Common (≥1/100 to <1/10) Dizziness, Fatigue (Nervous System), Nausea, Constipation (Gastrointestinal)
Uncommon (<1/100) Tachycardia (Cardiac), Rash (Skin and Subcutaneous Tissue)

Serious and Clinically Significant Adverse Reactions

Serious Hepatic Dysfunction: Regulatory documentation includes warnings regarding potential hepatic injury, which may manifest as elevated liver enzymes or jaundice. Immediate discontinuation and monitoring are required if this occurs.

Hypersensitivity: Rare, but serious, hypersensitivity reactions such as anaphylaxis have been reported. Neurotoxicity, including seizures, is a documented risk, particularly when high doses are used or in patients with impaired renal function.

Safety Restrictions and Monitoring

Contraindications: Lakea is contraindicated in patients with a known hypersensitivity to the drug substance or any of its components. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI, is strictly contraindicated due to the risk of Serotonin Syndrome.

Population-Specific Cautions: Caution is advised for use in the geriatric population due to increased susceptibility to sedating effects. Renal impairment requires dose adjustment due to effects on drug metabolite clearance, and use may be contraindicated in severe impairment. Monitoring of hepatic function is required before and periodically during prolonged treatment.

Overdose and Emergency Response

The official regulatory profile for Lakea overdose centers on cardiovascular system collapse due to the drug’s exaggerated effects. The most likely documented presentations are hypotension (excessively low blood pressure), often leading to symptoms such as dizziness and syncope (fainting). Regulatory documents also list potential heart rate abnormalities, including both tachycardia (fast heart rate) and bradycardia (slow heart rate).

The most severe documented outcomes are profound hypotension, which carries a risk of shock, and subsequent acute kidney injury and hyperkalemia. The official guidance mandates that urgent medical help must be sought immediately. Individuals should contact a Poison Help line and call emergency services if the person has collapsed, lost consciousness, or is experiencing difficulty breathing.

Management procedures are defined as symptomatic and supportive treatment because no specific antidote is known for Losartan overdose. Key measures include the administration of intravenous fluid infusions to counteract symptomatic hypotension, as specified in prescribing information. Regulatory authorities require continuous hospital monitoring of vital signs, fluid status, and laboratory tests for renal function and electrolytes. Furthermore, neonates with in-utero exposure are a population-specific consideration and must be observed for the development of hypotension and hyperkalemia.

Therapeutic Uses of Lakea

What Lakea Treats: Main Uses and Benefits

The primary goal of Lakea is to provide supportive therapeutic relief by addressing groups of challenging symptoms across several key domains, helping patients cope more steadily with difficult or persistent episodes. The medication is commonly used across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort. Its applications include providing support for the management of chronic discomfort.

Lakea is relevant for easing symptoms related to physical discomfort in conditions such as neuropathic pain (nerve-related burning and tingling), fibromyalgia (widespread body aches and stiffness), and as supportive management for opioid use disorder (reducing withdrawal distress and cravings). This assistance is applied in situations involving certain distressing symptoms, contributing to the management of conditions characterized by periods of heightened symptoms. The assistance may help patients cope more steadily with symptom fluctuations, and supports general well-being during symptomatic phases.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus Overview of Pregabalin

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lakea

Official regulatory documents define eligibility for Lakea (Losartan) based on absolute contraindications and specific population limitations.

Contraindicated Populations (Must Not Use) Age and Organ Function Restrictions
Pregnancy: Absolutely prohibited during the second and third trimesters. Discontinuation is required immediately upon pregnancy detection. Use is also not recommended during the first trimester.
Pediatric Use: Not recommended for children under the age of six years, as safety and efficacy in this group are not established.
Severe Hepatic Impairment: Contraindicated due to the risk of drug accumulation and lack of therapeutic experience in severe cases.
Hypersensitivity: Prohibited for patients with a known allergy to Losartan or any component of the medicine.
Aliskiren Co-Therapy: Prohibited in patients with diabetes mellitus who are taking medications containing aliskiren.
Lactation: Use is generally not recommended while breastfeeding.

Condition-Specific Eligibility Rules

Adult patients are generally eligible for use. However, individuals with volume or salt depletion (e.g., from high-dose diuretics) must have this condition corrected prior to treatment. Use in pediatric patients with a glomerular filtration rate below 30 mL/min/1.73 m^2 is not recommended. The eligibility profile establishes clear boundaries, defining which physiological states, age groups, and concurrent therapies prohibit or restrict use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions with Lakea as documented in official regulatory labeling, including those that modify drug exposure or clinical effect.

Pharmacokinetic Interactions

Lakea is identified in regulatory documentation as a weak inhibitor of the CYP2D6 enzyme and a substrate for the P-glycoprotein (P-gp) efflux transporter. Co-administration with strong CYP3A4 inducers (e.g., [Inducer Drug]) results in a clinically significant reduction in Lakea exposure (AUC/Cmax). Conversely, co-administration with BCRP inhibitors is documented to increase Lakea plasma concentrations.

Pharmacodynamic Interactions

Use with other medications that prolong the QT interval (e.g., [QTc-Prolonging Drug]) carries a documented risk of additive effects on the QT interval. An increased risk of central nervous system (CNS) depression is noted when Lakea is combined with other CNS depressants.

Contraindications and Administration Constraints

Co-administration with specific agents, including [Contraindicated Drug 1], is strictly forbidden due to documented safety concerns. Alcohol consumption is also contraindicated. For certain agents, such as Chelating Agents, the official label requires administration to be separated by at least 4 hours before or 6 hours after the Lakea dose to prevent reduced absorption.

Population-Specific Notes

The interaction severity with certain CYP Inhibitor Drugs is documented to be exaggerated in individuals with severe hepatic impairment.

Mechanism of Action

Selective AT1 Receptor Blockade

Losartan's action begins at the molecular level by functioning as a selective antagonist (blocker) of the Angiotensin II Type 1 receptor ( AT1). By preventing the Angiotensin II ( AII) hormone from binding to this receptor, the drug interrupts the signaling step that normally drives vessel contraction and aldosterone release. This is a direct intervention in the body's Renin-Angiotensin-Aldosterone System (RAAS).


Cascade: Modulating Vascular Tone and Fluid Homeostasis

This molecular interference initiates a cascade that alters the underlying physiology of pressure regulation. The AT1 receptor blockade leads directly to the vasodilation (widening) of blood vessels, which reduces the mechanical total peripheral resistance to blood flow. Concurrently, the suppression of AII-mediated aldosterone secretion reduces the renal retention of sodium and water, influencing overall circulating fluid volume. These actions adjust the regulatory feedback mechanisms within the RAAS pathway.


Physiological Effect: Lowering Peripheral Resistance

The combined effect of reduced peripheral resistance and subtle changes in fluid retention results in an alteration of the physiological state of the circulatory system. The mechanism modulates systems where AII-mediated signaling promotes blood vessel contraction and influences volume regulation. This mechanism leads to physiological adjustments that define the drug's overall pharmacodynamic profile.

Dosage and Administration Information

How to Use Lakea: Official Administration Guidelines

Lakea (Losartan potassium) is administered according to a highly standardized, long-term protocol. It is supplied for oral administration as tablets (25 mg, 50 mg, 100 mg) or as a specially prepared oral suspension.


Dosage and Schedule

The standard dosing schedule for adults is once daily. Therapy typically initiates with a 50 mg dose. The maximum daily dose is 100 mg. Dose adjustments, if needed, are generally evaluated and implemented after several weeks to reach the optimal level for chronic management. The tablets may be taken with or without food, establishing a flexible timing for daily use.

Special Administration Rules

Population Adjustments: A lower initial dose of 25 mg once daily is specifically required for certain populations, including adults with mild-to-moderate hepatic impairment or those who are intravascularly volume-depleted. For pediatric patients aged 6 years and older, dosing is based on body weight, starting at 0.7 mg/kg up to 50 mg once daily.

Handling Missed Doses: If a scheduled dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose must be skipped; a double dose should never be taken. The liquid suspension formulation requires that the medicine be accurately measured using a calibrated device and shaken well before each administration.


Connection to Protocol:

These instructions define a chronic, once-daily oral administration protocol that permits flexibility with food but strictly mandates specific lower starting doses for vulnerable patient groups. This structure establishes clear limits on dosage and provides an established protocol for managing dosing errors.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research surrounding this compound has primarily focused on its application in adult populations. Studies evaluated whether it could affect outcomes in the management of specific conditions. Findings have been published in peer-reviewed literature. The research summarized here focuses exclusively on the measured findings from clinical trials.


Possible Biological Activity

Research has been conducted to understand the compound's possible biological activity. Studies also assessed the compound's effects on biological indicators. Initial findings from in vitro studies indicated a potential effect on cellular signaling involved in the disease process; however, the precise biological mechanism remains under investigation.


Efficacy and Outcome Measures

Clinical trials have investigated the compound's effect on various patient-reported and clinical measures.

Symptom Management

Studies focused on whether there was a correlation with a reduced severity of symptoms, particularly pain and inflammation, across a treatment course lasting 12 weeks. Findings from trials indicated a measured reduction in the average pain score recorded by participants compared to those in the placebo group. Research investigated whether the time to onset of potential effect in individuals with acute exacerbations was measurable within the first week of administration.

Quality of Life

Results from certain studies showed an improvement in measured quality of life metrics, which were tracked using standardized patient questionnaires. These metrics included assessments of mobility, sleep, and overall daily functioning. Research evaluated the therapy over a specific period, though long-term observational data remain limited.


Tolerability Profile Assessment

Research assessed the compound's tolerability across various patient groups. Tolerability and adverse event rates were measured in trials lasting up to 52 weeks. The most commonly reported side effects included mild gastrointestinal upset and headache.

Studies also investigated potential drug interactions with other agents. Exclusion criteria were applied in clinical trials, often involving individuals with severe renal impairment or a history of specific cardiovascular events, to manage study variables. Research focused on measuring specific endpoints, such as changes in liver enzyme levels, and did not extend to providing general advice on drug suitability for those with pre-existing conditions.

Frequently Asked Questions (FAQ)

Common questions about Lakea (FAQ)


Q: Do I need to change my diet while I am taking Lakea?

Official medication labeling indicates that it is important to be aware of potassium intake while using Lakea (Losartan). Lakea may increase potassium levels in the blood, and official documentation advises against the use of potassium supplements or salt substitutes containing potassium. Discussion of diet and supplements with a healthcare provider is generally recommended.

Q: Does Lakea have a risk of becoming habit-forming?

According to regulatory information, Lakea (Losartan) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major organizations. This classification indicates that the medication is viewed as having a low potential for misuse or abuse.

Q: Can Lakea be taken at the same time as cold and flu medicine?

Some common cold and flu medicines contain ingredients known as sympathomimetic agents (such as pseudoephedrine) that may temporarily increase blood pressure and heart rate. Because Lakea is used to manage blood pressure, the combined use of these agents may lead to adverse cardiovascular effects, and official guidance advises caution for co-administration.

Q: Are there any specific safety classifications for Lakea, like a boxed warning?

Yes, official FDA product information includes a Boxed Warning, which is the agency's most serious safety alert for drug products. The warning is regarding the risk of fetal harm or death if Lakea (Losartan) is taken during the second and third trimesters of pregnancy.

Q: What are the known interactions between Lakea and supplements or herbal products?

The official product information specifically advises against the use of potassium supplements or salt substitutes containing potassium. These products can increase the risk of high potassium levels in the blood (hyperkalemia) when combined with Lakea.

Q: Why do some people refer to Lakea by a different, informal name?

Lakea is the brand name designated for this medication. The active ingredient within the tablets is Losartan, which is the generic name. Patients and prescribers may use the generic name, Losartan, or other brand names used in different regions, such as Cozaar.

Q: Is Lakea the same active ingredient as other drugs with different names?

Yes, the single active ingredient in Lakea is Losartan (specifically Losartan potassium). This same active ingredient is sold under its generic name by multiple manufacturers and under various other brand names internationally.

Q: How quickly does Lakea leave the body after I stop taking it?

Pharmacokinetic data from regulatory documents show that the most important component of the drug's activity, the active metabolite, has a terminal half-life of approximately 6 to 9 hours. The half-life is the time it takes for half of the substance to be eliminated from the body.

Q: Does Lakea interact with common pain relievers like ibuprofen?

Official labeling advises caution when combining Lakea with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen. The co-administration of NSAIDs is associated with a potential for decreased blood pressure-lowering effect and could increase the risk of worsening kidney function.

Q: What if I experience a side effect that isn't listed in the official documents?

Regulatory agencies, such as the FDA, have formal programs for monitoring drug safety. Reporting mechanisms for adverse drug experiences are available to both patients and prescribers, including for side effects that are not currently listed in the official documentation.

Q: Has Lakea been approved in other countries besides the US?

Yes, the active ingredient Losartan has been approved for sale and use by regulatory bodies in countries across the globe, including those in Europe and other regions. It is often sold under different brand names in these international markets.

Q: Does Lakea interact with caffeine or energy drinks?

The official product labeling does not list a direct interaction with caffeine. However, high intake of caffeine may temporarily raise blood pressure, which could work against the effects of an antihypertensive medicine like Lakea.

Q: Why is Lakea prescribed for different conditions?

The FDA-approved uses for Lakea (Losartan) include the management of high blood pressure (hypertension). It is also prescribed to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for the treatment of diabetic kidney disease (nephropathy) in patients with type 2 diabetes.

Q: Are there any restrictions on donating blood while taking Lakea?

Major regulatory guidelines for blood donation typically indicate that taking blood pressure medication like Losartan does not automatically disqualify a donor. Eligibility is generally determined by the blood collection center based on the donor's current health status at the time of donation.

Q: What documents should I read to find the official information about Lakea?

The most complete and official information can be found in documents prepared for patients and healthcare professionals. These include the Patient Medication Information leaflet, the Summary of Product Characteristics (SmPC) in some regions, and the complete FDA Prescribing Information (Drug Label).

Q: Does the effectiveness of Lakea change over time?

Pharmacokinetic studies cited in regulatory information indicate that the way the body processes Losartan and its active metabolite does not change over time with repeated once-daily dosing. The drug does not accumulate in the bloodstream with consistent use.

Q: Can I take Lakea if I am taking over-the-counter stomach acid reducers?

Clinical studies have found no clinically significant pharmacokinetic interaction between Losartan and common over-the-counter stomach acid reducers, such as H2 antagonists (like famotidine) or other antacids.

Q: Is it safe to suddenly stop taking Lakea?

Official documentation reports that abrupt withdrawal of Losartan has not been associated with rebound hypertension (a sudden, significant increase in blood pressure). However, any change to a prescribed long-term regimen is a decision that requires discussion with a healthcare provider.

How should Lakea be stored and disposed of?

The official storage and disposal requirements for Lakea (Losartan) tablets are explicitly defined by regulatory bodies to maintain product stability and ensure environmental protection.

Official Storage and Handling

Storage Scope Mandatory Requirement
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep the medicine in its original container, tightly closed, protected from moisture and excessive heat.
Safety The product must be stored out of the reach and sight of children.
Prohibition Keep from freezing (FDA Drug Labeling).

Official Disposal Instructions

Regulatory agencies emphasize that unused or expired Losartan should not be flushed down the toilet or disposed of in wastewater due to environmental concerns. The preferred method for discarding the medicine is through an official drug take-back program. If a take-back program is unavailable, official guidelines permit disposal in household trash only after the tablets are mixed with an undesirable substance, such as dirt or used coffee grounds, and sealed in a plastic bag to prevent accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lakea found in:

A-Z Index: